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doi:10.1016/j.ejvs.2008.02.016Abstract Objectives: To investigate the relationship between the PlA1/A2 polymorphism and
platelet activation and aggregation in patients with Peripheral Arterial Disease (PAD).
Design: A prospective single-centre cohort study.
Methods: 45 patients with PAD on aspirin 75 mg were recruited and phenotyped/genotyped for
the Gp IIb/IIIa PlA1/A2 polymorphism. Platelet-Monocyte Aggregation (PMAs) was evaluated
using flow-cytometry.
Results: The formation of PMAs in the PlA2 group was higher but not statistically significant
(pZ 0.17). However, when males were analysed separately, the formation of PMAs was signif-
icantly higher in the PlA2 group (pZ 0.0192). No difference was seen in the females.
Conclusions: In this study we show that the PlA1/A2 polymorphism primarily affects the aggre-
gation of platelets to monocytes in males. The effect is not observed in females and under-
standing the mechanism behind this may help elucidate the way the polymorphism alters
platelet function in the presence of aspirin.
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Atheroma is a leading cause of morbidity and mortality
throughout the world. Platelets contribute to the pro-
gression of atherosclerotic disease by adhering to the
subendothelial matrix at sites of shear-induced mechanical
injury to the vessel. Enhanced platelet activation andd by Elsevier Ltd. All rights reserved.
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the pathophysiology of such events. The understanding that
genetic factors play a role in the development of atheroma
led to recent interest in polymorphisms of platelet re-
ceptors as a possible basis for this. Furthermore, there is
a growing body of evidence to link these polymorphisms
with resistance to antiplatelet agents,1e3 the implications
of which are not yet fully appreciated.
Several genetic variants have been identified in the
platelet receptor GPIIb/IIIa and attempts have been made
to ascribe these to functional outcomes. The most studied
sequence has been the PlA1/A2 (HPA-1) polymorphism, for
which approximately 25% of Caucasians carry the variant
A2 allele. The polymorphism results from a substitution
of cytosine to thymidine at position 1565 on exon 2 of
the GPIIIa gene. This point mutation results in the amino
acid substitution of proline (Pro) to leucine (Leu) at posi-
tion 33 in GPIIIa. The leucine-33 allele is known as PlA1
(HPA-1a) and has a frequency of 0.85. The proline-33 allele
is known as PlA2 (HPA-1b) and has a frequency of 0.15.
Genotypes can be PlA1/A1, PlA1/A2 or PlA2/A2 depending on
simple Mendelian inheritance of the alleles. Controversy
exists as to the exact clinical consequence of the polymor-
phism, with various previous studies resulting in conflicting
results with regards to platelet activity.4e8 These popula-
tion studies have shown that the polymorphism may
worsen, have no effect or even improve clinical outcome
from atheroma. This raises questions about how the
polymorphism exerts its effect on patients, with aspirin
resistance being one possible explanation for the wide
variation in results. Understanding the underlying bio-
chemical mechanisms behind the polymorphism effect is
essential to explain the clinical differences seen in order
to apply knowledge of the polymorphism in a clinical
context.
The binding of platelets to leucocytes is an important
part of their activation pathway. Detection of this in-
teraction has been shown to be a sensitive marker of
platelet activation.9 Flow cytometry can detect both plate-
lets and leucocytes and determine if they are bound to one
another using specific antibodies to unique surface
proteins.
Previous studies on patients with atheroma have
shown increased platelet activation in the form of
fibrinogen binding, direct platelet aggregation and
surface markers of platelet activation (e.g. PAC-1, P-
selectin).5,10e12 Other studies, however, have shown that
platelets are unaffected and even protected from activa-
tion by the PlA2 allele.13,14 These studies have been
performed in the context of healthy volunteers however,
and as such extrapolation of the results into patients
with vascular disease is difficult. This study uses plate-
let-monocyte binding as a marker of platelet activation.
This has been shown to be a more sensitive marker
than fibrinogen binding or surface markers and perhaps
gives an indication of chronic platelet activation rather
than simply the acute activation seen well with other
tests.9
The aim of this study was to investigate the link between
the PlA1/A2 polymorphism and platelet aggregability/activa-
tion in a population of patients with peripheral arterial
disease (PAD).Methods
Ethical approval was granted from the local ethics commit-
tee. 45 Patients with PAD were recruited from patients
attending the vascular unit at the Queen Elizabeth Hospi-
tal, Gateshead, UK. All patients had a history suggestive of
stable Intermittent Claudication (IC) and an Ankle Brachial
Pressure Index (ABPI) of less than 0.9 or radiologically
proven vascular disease on angiography or duplex ultra-
sound. No patients had rest pain or critical ischaemia. All
patients gave written consent to participate in the study.
Patients with concomitant inflammatory processes or with
conditions known to affect platelet function were ex-
cluded. Specific exclusions were patients with diabetes
mellitus, critical ischaemia, active ulceration or gangrene,
malignancy or infection. Patients were all taking 75 mg of
aspirin daily and were on no other antiplatelet agents or
anticoagulants for the duration of the study.
Phlebotomy
A standardised phlebotomy technique was used which has
been previously advocated for platelet work.15e17 Vene-
puncture was performed with patients sitting upright after
at least 10 minutes of rest. No tourniquet was used where-
ever possible, but on occasions was used to find a suitable
vein, then released before any sample was drawn. The first
4 ml of blood was discarded, or used for unrelated tests
(e.g. Cholesterol level). Vacutainers (Becton-Dickinson,
Cambridgeshire, UK ) were employed to standardise the
rate of phlebotomy and minimise unnecessary handling of
the samples. For polymorphism phenotyping, platelet flow
cytometry and platelet aggregation tests, samples were
collected in 0.109 M trisodium citrate in a 1:9 dilution
(citrate:blood). For DNA analysis, blood was collected in
plastic K2 EDTA tubes and for soluble P-selectin, blood
was collected in gold top BD tubes with a clot activator
gel (Becton-Dickinson, Cambridgeshire, UK ). Samples
used for phenotyping were stored at room temperature
and used within 24 hours as directed by the manufacturer.
Samples for platelet flow cytometry were prepared within 3
minutes as described below. Samples for DNA analysis were
frozen within 24 hours at 20 C and thawed once required.
Phenotyping
Detection of the PlA phenotype by flow cytometry has been
described previously,18 although no formal validation of the
commercially available kit (American Diagnostica, USA)
exists in the literature. We used this single-colour flow
cytometric technique to elicit patient PlA status and then
validated our own results using the gold-standard PCR.
RFLP-PCR
Restriction-Fragment Length Polymorphism (RFLP-PCR)
was used to ascertain genotype as previously de-
scribed.4,5,10,19,20 Samples were stored at 20 C in K2
EDTA tubes. After thawing, aliquots of blood underwent
DNA extraction using the automated BioRobot M48 worksta-
tion (Qiagen Ltd, UK ). Essentially cells were lysed, then
Table 1 Patient demographics
PlA1 PlA2 PlA1 v PlA2
Mean age 68.8 65.9 pZ 0.421*
Male (%) 26 (76.5) 6 (54.5) pZ 0.163**
Active smokers (%) 9 (26.5) 5 (45.5) pZ 0.237**
Mean cholesterol 4.84 4.77 pZ 0.841*
Ischaemic heart
disease (%)
14 (41.1) 4 (36.4) pZ 0.777**
Previous cerebral
event (%)
0 (0) 3 (27.3) pZ 0.002**
Percentage of total patients shown in brackets.
* Mann-Whitney test.
** Chi-Square test.
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nucleic acids; MagAttract particles were efficiently sepa-
rated by applying a magnet to the pipette tips and washing
to remove contaminants; elution reagent was added to the
washed magnetic particles and the mixture was heated to
optimize the yield of nucleic acid.
Primers were manufactured as previously described20
(Invitrogen, Paisley, UK ) and diluted in purified water to
25 mM. DNA was diluted in purified water to give a final
concentration of 25e50 ng/mL. Amplification of the
sequence to give a 338 bp product was performed using
HotstarTaq DNA polymerase (Qiagen Ltd, UK ). Several
‘blank’ samples were amplified as controls for contamina-
tion. The restriction endonuclease used for the digest was
ScrFI which digests CC’NGG sequence. With this PCR prod-
uct, the enzyme digested the PLA1 allele into 3 fragments;
214 bp, 46 bp and 78 bp. The PLA2 allele was digested fur-
ther due to the nucleotide base substitution into fragments
of 77 bp, 137 bp, 46 bp and 78 bp. The fragments were sep-
arated and identified by 2.2% agarose gel electrophoresis
with ethidium bromide staining.
Platelet monocyte aggregation
The technique used here is based on that first developed by
Li et al.9 It was modified for our purposes to focus on mono-
cytes rather than all leucocytes with the addition of the
monocyte specific CD14 antibody. It is a three-colour
flow-cytometric technique which uses whole blood with
minimal sample manipulation.
10 ml of bloodwas added to apre-mixed tube of antibodies
containing; 20 ml CD61-FITC (Becton Dickinson, Oxford, UK ),
5 ml CD14-PE (DakoCytomation, Cambridgeshire, UK ), 7 ml
CD45-PerCP (DakoCytomation, Cambridgeshire, UK ) and
60 ml PBS. A second tube was used as an isotype control and
was mixed in the same way except for substituting the
CD61-FITC for 20 ml IgG1-FITC (Becton Dickinson, Oxford,
UK ). The tubes were then incubated in the dark for 20 min-
utes before the addition of 1 ml of fixative.
Flow cytometry was performed within 2 hours of fixation
using a Becton Dickinson FACScan Flow Cytometer. 500
monocytes were collected for analysis on WinMDI 2.8.
A dotplot of CD14 versus CD45 was used to identify the
monocyte population. This was then gated and a histogram
of CD61 binding calculated. This is a measurement of
platelet aggregation to the monocytes and was calculated
as percent positive cells (PPC).
Application of the platelet-monocyte binding data for
determination of aspirin resistance was done using a cut-off
value above which platelets were considered to be in-
adequately ‘blocked’ by aspirin. This has been used in the
past by several groups to define aspirin resistance in-
vitro,21e23 although standardisation between methods
makes it difficult to apply these values directly. Previous
attempts to define a cut-off have shown approximately
5e60% of the population to be inadequately treated by
aspirin.24 Using this method, a cut-off was defined as the
mean binding (12.5% platelet to monocyte aggregates).
Some studies have identified a link between oestrogens
and platelet function in regard to the PlA polymor-
phism.25,26 The authors of these papers concluded that
oestrogens may protect against the effect of thepolymorphism. Analysis of the sexes individually was there-
fore performed.
Results
45 patients were recruited into the study and divided into 2
groups; PlA1 homozygotes and PlA2 homozygotes/heterozy-
gotes. The two groups were well matched in terms of demo-
graphics (see Table 1), although significantly more PlA2
carriers had had a previous stroke or TIA than the PlA1 ho-
mozygotes. 11 patients (24.4%) carried the PlA2 allele with
the remaining 34 patients belonging to the PlA1 homozygote
group in concordance with previously published figures.4 2
patients were homozygous for the PlA2 allele (1 male, 1 fe-
male) and were included with the heterozygotes for the
purpose of analysis.
Overall Platelet Monocyte Aggregates (PMA) showed
a non-significant (pZ 0.17, Mann-Whitney Test) trend to-
wards a difference between the genotypes (Fig. 1). Further
analysis of the PMA was carried out by defining a cut-off
value at which the platelet was not effectively inhibited
from aggregation by aspirin (Mean aggregation, 12.5%).
38% of the population lay above this value and would be
considered aspirin resistant. A chi-squared analysis reveals
significantly more PlA2 carriers in the aspirin resistant group
(pZ 0.04) and is shown in Fig. 2.
Sex differences
The females in the study showed no significant difference
between the genotypes (pZ 0.62, Mann-Whitney test), but
the males showed stronger differences than in mixed sex,
achieving significance in the PMA test directly (10.9% PlA1
versus 18.4% PlA2, pZ 0.02, Mann-Whitney test) and using
an aspirin resistance cut-off value of the mean PMA as pre-
vious (pZ 0.01, Chi-squared test). These results are shown
in Figs. 1 and 2.
Discussion
In this study we have shown that the PlA1/A2 polymorphism
primarily affects the aggregation of platelets to monocytes
in male claudicants. The effect is not observed in females
and understanding the mechanism behind this may be key
Figure 1 Platelet Monocyte Aggregation in PlA1 versus PlA2.
Mann-Whitney test shows a trend towards higher binding in
PlA2 genotype but is not significant (pZ 0.17) in both sexes
combined (left). PMA formation by genotype in males only is
significant (pZ 0.019) (right).
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function in the presence of aspirin. Platelet-monocyte in-
teraction has been shown previously in clinical situations
such as during cardiopulmonary bypass,27 angioplasty,28e30
stroke31 and ischaemic heart disease.32,33 The role of these
aggregates is not fully understood, but it is known that leu-
kocytes are activated by such an interaction with plate-
lets.34,35 Platelet adhesion to monocytes is mediated by
P-selectin (CD62P), the counter receptor on monocytesFigure 2 Aspirin resistance as defined by PMA formation
above the mean aggregation of 12.5%. Significantly more pa-
tients with the PlA2 allele are found in the aspirin resistant
group (pZ 0.0418, Chi-squared test). This association is stron-
ger in the males (pZ 0.0101) but not evident in the females
(pZ 0.9282).being PSGL-1.36 There is also evidence to show that GP
IIb/IIIa has a role to play in platelet-leukocyte interac-
tions,37,38 monocytes binding fibrinogen via MAC-133,39 to
this integrin. May et al. showed the binding of platelets
to monocytes appeared to be blocked by antiplatelet
agents,33 although they used a combination of agents in
their study, possibly negating the effects of resistance to
the agents. A plausible explanation of the results seen
here is that the polymorphism directly affects either the
GP IIb/IIIa receptor, or the aspirin effect on that receptor,
and hence alters the interaction of the platelet and mono-
cyte. This modified reaction has the potential to worsen
atheroma via inflammatory and other pathways, leading
to poorer clinical outcomes seen in various studies of the
PlA1/A2 polymorphism. This complex chain of events may
also go some way to explaining the heterogeneous results
of other studies, as different methods of assessing platelet
function may not be as sensitive to the effects shown here.
Indeed, platelet-monocyte aggregates have been shown to
be one of the most sensitive methods of detecting platelet
activation available to researchers.40
In our study, we were unable to draw any conclusions
about the difference between heterozygote carriers of the
PlA2 allele and homozygote carriers due to the small num-
ber of homozygotes in our study. However, it is interesting
to note that both homozygotes were in the aspirin resistant
group, and moreover, the male homozygote had the highest
PMA binding in the study at 32.13% (compared to a mean of
12.5%). Larger studies would enable the separate analysis
of the 3 genotypes to further delineate any cumulative
effect of the PlA2 allele.
The sex difference seen in this study may simply reflect
the background difference in platelet activation between
men and women. However, there is some evidence to show
that oestrogens may play a role in the pathophysiology of
the polymorphism25,26 and as such may lead to the pro-
nounced effect in men as seen here. As all our patients
are post-menopausal, oestrogen levels alone cannot fully
explain the effect seen here.
The interaction is a complex one between oestrogen
levels and the levels/number/types of receptors for these
oestrogens on the platelet surface. It is more likely that it is
this interaction that modulates the effect rather than the
amount of oestrogen per se. Studies have shown that the
platelet-monocyte interaction varies with the menstrual
cycle41 and also that after the menopause, there is a de-
creased platelet activation status compared with premeno-
pausal women.42 Clearly further work needs to be done to
investigate this important link between sex and platelet ac-
tivation and the effect of this link on genetic polymorphisms.
To date no study has shown such a marked difference
between men and women with the polymorphism in-vivo.
The issue of compliance with medication is a possible
factor in the resistance to aspirin. However, we have no
reason to believe that there should be a difference in
compliance due to the polymorphism studied here.
The future of antiplatelet therapy is likely to involve
‘tailoring’ a regimen to individual patients. Large studies
have shown unequivocally the benefit of aspirin to the
population,43e46 however this effect is not universal to the
individual and the reasons behind this are only just becom-
ing clear. Studies such as CAPRIE47 reveal an improvement
136 J. McCaslin et al.in outcome when using Clopidogrel compared to aspirin and
a more pronounced benefit is seen when combined agents
are used, as in the CURE trial.48 These studies suggest
that certain patients do better on agents other than aspirin
and by identifying these patients they can be treated with
higher dose, alternative or combined antiplatelet thera-
pies. Identifying the patients at high-risk of vascular events
despite taking aspirin is now the subject of vigorous re-
search. It is anticipated that surrogate tests such as genetic
screening for recognised polymorphisms such as PlA1/A2 will
form the basis of the individualisation of antiplatelet ther-
apy. Clearly much more work is needed before we can fully
understand the basis of aspirin resistance, along with work
to look at resistance to other agents and whether there is
a benefit to swapping agents in-vitro. After this, larger clin-
ical trials will be needed to determine if those results seen
in the laboratory setting transfer to genuine clinical bene-
fit. This study adds further weight to the growing body of
evidence to show that patients with the PlA2 allele have
higher levels of platelet activation than those without,
even in the presence of aspirin, and that this may be one
of a host of genes soon to be screened in the routine treat-
ment of patients with atheroma.
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